BlackRock, Melkart Resume Grifols Purchases Amid Takeover Bid
Both funds are increasing their stakes in Grifols amid speculation about the valuation Brookfield’s bid for the drugmaker could achieve.
Grifols shares are continuing their rally today, boosted by a 9.70% gain last Monday, which was recorded on Monday on news of a takeover bid being considered by Brookfield. The pharmaceutical company made a share purchase on the same day.them, among others, Melkart Opportunities Master Fund.
Today’s CNMV reports include the increase in participation reported by Melkart. The fund now has
Grifols shares are continuing their rally today, boosted by a 9.70% gain last Monday, which was recorded on Monday on news of a takeover bid being considered by Brookfield. The pharmaceutical company made a share purchase on the same day.them, among others, Melkart Opportunities Master Fund.
Today’s CNMV reports include the increase in participation reported by Melkart. The fund now has 1,109% capital of Grifols. The company told the CNMV that it was July 8th last yearon the first day when the news of the takeover came out, when exceeded the 1% threshold.
In her previous post on May 16, she said 0.90%. He previous increase in participation Melqart is dated by the month Marchwhen he notified 1.124% of the capital.
Like Melqart, BlackRock The company has not notified the CNMV of an increase in its stake in Grifols since March. The world’s largest manager has increased his weight in the pharmaceutical company up to 4,438%.
In its previous notification to the CNMV reports on 13 March, it indicated a participation of 4.304%.
Grifols shares, listed on the Ibex exchange, resumed their rise today to hovering around the ten euro level.
As published today by EXPANSIÓN, Brookfield’s preliminary proposal, which is subject to review, sets a price range, the lower limit of which is around 10 euros per share.